NASDAQ:CALT Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free CALT Stock Alerts $17.88 -0.20 (-1.11%) (As of 01:39 PM ET) Add Compare Share Share Today's Range$17.50▼$19.1950-Day Range$17.55▼$23.1852-Week Range$15.25▼$29.30Volume1,453 shsAverage Volume7,920 shsMarket Capitalization$532.65 millionP/E RatioN/ADividend YieldN/APrice Target$34.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Calliditas Therapeutics AB (publ) alerts: Email Address Calliditas Therapeutics AB (publ) MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside77.2% Upside$34.00 Price TargetShort InterestHealthy0.01% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth1,089.66%From $0.29 to $3.45 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.86 out of 5 starsMedical Sector388th out of 910 stocksPharmaceutical Preparations Industry174th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingCalliditas Therapeutics AB (publ) has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCalliditas Therapeutics AB (publ) has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.01% of the outstanding shares of Calliditas Therapeutics AB (publ) have been sold short.Short Interest Ratio / Days to CoverCalliditas Therapeutics AB (publ) has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calliditas Therapeutics AB (publ) has recently decreased by 56.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCalliditas Therapeutics AB (publ) does not currently pay a dividend.Dividend GrowthCalliditas Therapeutics AB (publ) does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CALT. Previous Next 1.9 News and Social Media Coverage News SentimentCalliditas Therapeutics AB (publ) has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Calliditas Therapeutics AB (publ) this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CALT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calliditas Therapeutics AB (publ) insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of Calliditas Therapeutics AB (publ) is held by insiders.Percentage Held by InstitutionsOnly 2.83% of the stock of Calliditas Therapeutics AB (publ) is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Calliditas Therapeutics AB (publ) are expected to grow by 1,089.66% in the coming year, from $0.29 to $3.45 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Calliditas Therapeutics AB (publ) is -11.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Calliditas Therapeutics AB (publ) is -11.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalliditas Therapeutics AB (publ) has a P/B Ratio of 18.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT)Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.Read More CALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CALT Stock News HeadlinesApril 21, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Up 3.4%April 19, 2024 | benzinga.comLatest News for Calliditas Therapeutics Stock (NASDAQ:CALT)April 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 19, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $17.80April 18, 2024 | prnewswire.comCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024April 13, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Down to $21.52April 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Calliditas Therapeutics Amid Positive Market Trends and Upcoming CatalystsApril 9, 2024 | finance.yahoo.comCalliditas Therapeutics to Attend Conferences in AprilApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 9, 2024 | prnewswire.comCalliditas Therapeutics to Attend Conferences in AprilApril 8, 2024 | markets.businessinsider.comCalliditas Gets Notice Of Allowance For U.S. Patent Application Covering Setanaxib To Treat CancerApril 8, 2024 | prnewswire.comCalliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresApril 8, 2024 | prnewswire.comCalliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentApril 7, 2024 | cnn.comCalliditas Therapeutics AB Sponsored ADRMarch 11, 2024 | prnewswire.comEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®March 6, 2024 | finanznachrichten.deCalliditas Therapeutics: Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYOMarch 6, 2024 | finanznachrichten.deCalliditas Therapeutics: Calliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®March 6, 2024 | prnewswire.comCalliditas announces an additional seven year orphan drug exclusivity period for TARPEYO®March 1, 2024 | prnewswire.comCalliditas Therapeutics to Attend Investor Conferences in MarchFebruary 26, 2024 | msn.comFulcrum Therapeutics Q4 2023 Earnings PreviewFebruary 25, 2024 | msn.comCalliditas Therapeutics AB (CALT) Price Target Increased by 5.27% to 42.86February 22, 2024 | finance.yahoo.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | markets.businessinsider.comCalliditas Therapeutics: Strong Sales and FDA Approval Propel Buy RatingFebruary 21, 2024 | prnewswire.comCalliditas Year-end report, January - December 2023February 14, 2024 | finance.yahoo.comInvitation to the presentation of Calliditas´ Year-end report January - December 2023February 14, 2024 | prnewswire.comInvitation to the presentation of Calliditas´ Year-end report January - December 2023February 13, 2024 | msn.comAN2 Therapeutics extends losses as Leerink cuts on trial setbackSee More Headlines Receive CALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today4/23/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CALT CUSIPN/A CIK1795579 Webwww.calliditas.se Phone46-0-841-130-05FaxN/AEmployees192Year Founded2004Price Target and Rating Average Stock Price Target$34.00 High Stock Price Target$50.00 Low Stock Price Target$18.00 Potential Upside/Downside+86.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E Ratio63.00 P/E GrowthN/ANet Income$-43,960,000.00 Net Margins-38.72% Pretax Margin-37.87% Return on Equity-104.47% Return on Assets-26.75% Debt Debt-to-Equity Ratio2.89 Current Ratio3.13 Quick Ratio3.08 Sales & Book Value Annual Sales$113.78 million Price / Sales4.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book17.24Miscellaneous Outstanding Shares29,790,000Free Float29,135,000Market Cap$544.26 million OptionableOptionable Beta1.51 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Renee Aguiar-Lucander (Age 62)Chief Executive Officer Comp: $8.99MMr. Fredrik Johansson (Age 47)Chief Financial Officer Dr. Johan Haggblad Ph.D. (Age 66)Chief Scientific Officer Comp: $1.66MMr. Brian Gorman (Age 48)Group General Counsel Ms. Sandra Frithiof (Age 49)Head of Human Resources Ms. Ann-Kristin Myde BSc (Age 69)Head of Clinical Development & VP of Project Management Dr. Krassimir Mitchev (Age 65)Head of Medical Affairs Dr. Richard S. Philipson M.D. (Age 60)Chief Medical Officer Ms. Teona JohnsonHead of US MarketingMr. David FerraroHead of US SalesMore ExecutivesKey CompetitorsArbutus BiopharmaNASDAQ:ABUSPhibro Animal HealthNASDAQ:PAHCAltimmuneNASDAQ:ALTAcelyrinNASDAQ:SLRNIGM BiosciencesNASDAQ:IGMSView All CompetitorsInstitutional OwnershipOptiver Holding B.V.Bought 980 shares on 2/13/2024Ownership: 0.003%Simplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions CALT Stock Analysis - Frequently Asked Questions Should I buy or sell Calliditas Therapeutics AB (publ) stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CALT shares. View CALT analyst ratings or view top-rated stocks. What is Calliditas Therapeutics AB (publ)'s stock price target for 2024? 2 Wall Street research analysts have issued 1 year price targets for Calliditas Therapeutics AB (publ)'s shares. Their CALT share price targets range from $18.00 to $50.00. On average, they anticipate the company's share price to reach $34.00 in the next year. This suggests a possible upside of 77.2% from the stock's current price. View analysts price targets for CALT or view top-rated stocks among Wall Street analysts. How have CALT shares performed in 2024? Calliditas Therapeutics AB (publ)'s stock was trading at $25.74 at the start of the year. Since then, CALT shares have decreased by 25.4% and is now trading at $19.19. View the best growth stocks for 2024 here. Are investors shorting Calliditas Therapeutics AB (publ)? Calliditas Therapeutics AB (publ) saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 3,200 shares, a decline of 56.2% from the March 15th total of 7,300 shares. Based on an average daily volume of 7,900 shares, the short-interest ratio is presently 0.4 days. View Calliditas Therapeutics AB (publ)'s Short Interest. When is Calliditas Therapeutics AB (publ)'s next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our CALT earnings forecast. How were Calliditas Therapeutics AB (publ)'s earnings last quarter? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) posted its earnings results on Wednesday, February, 21st. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.02. The company earned $42.45 million during the quarter, compared to analysts' expectations of $36.24 million. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 104.47% and a negative net margin of 38.72%. During the same quarter last year, the business posted ($0.01) earnings per share. What other stocks do shareholders of Calliditas Therapeutics AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX). When did Calliditas Therapeutics AB (publ) IPO? Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 9,200,000 shares at $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager. How do I buy shares of Calliditas Therapeutics AB (publ)? Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CALT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
